immune system
• with expansion of the CD11c+ and CD19+ populations but decrease in dendritic cell and marginal zone B cells
|
• in the spleen
|
• peripheral to follicles
|
• as glomerular deposition, but not in the serum
|
• in the serum and as glomerular deposition
|
• in bone marrow-derived dendritic cells, total splenocytes, and splenic dendritic cells stimulated with R848, polyA:U, and any TLR7 ligand tested secrete more IL12b (IL-12p40) than similarly treated wild-type cells
• however, response to pCpG, polyI:C, and LPS is normal and serum level in R848-treated mice is normal
|
• in bone marrow-derived dendritic cells, total splenocytes, and splenic dendritic cells stimulated with R848, polyA:U, and any TLR7 ligand tested
• however, response to polyI:C and LPS is normal and serum level in R848-treated mice is normal
|
• mice exhibit an increase in IgG autoantibodies smRNP, RNP, and dsDNA compared with wild-type mice
|
• mice exhibit increased deposition of IgM, IgG, and C3 in the glomerulus compared with wild-type mice
|
renal/urinary system
• mice exhibit increased deposition of IgM, IgG, and C3 in the glomerulus compared with wild-type mice
|
homeostasis/metabolism
• in bone marrow-derived dendritic cells, total splenocytes, and splenic dendritic cells stimulated with R848, polyA:U, and any TLR7 ligand tested secrete more IL12b (IL-12p40) than similarly treated wild-type cells
• however, response to pCpG, polyI:C, and LPS is normal and serum level in R848-treated mice is normal
|
hematopoietic system
• with expansion of the CD11c+ and CD19+ populations but decrease in dendritic cell and marginal zone B cells
|
• in the spleen
|
• peripheral to follicles
|
• as glomerular deposition, but not in the serum
|
• in the serum and as glomerular deposition
|
growth/size/body
• with expansion of the CD11c+ and CD19+ populations but decrease in dendritic cell and marginal zone B cells
|